• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

跨越复杂次要组织相容性屏障的MHC I类限制性T细胞应答中的显性和隐蔽抗原:通过洗脱细胞肽进行分析和定位

Dominant and cryptic antigens in the MHC class I restricted T cell response across a complex minor histocompatibility barrier: analysis and mapping by elution of cellular peptides.

作者信息

Wolpert E, Franksson L, Kärre K

机构信息

Microbiology and Tumor Biology Center, Karolinska Institute, Stockholm, Sweden.

出版信息

Int Immunol. 1995 Jun;7(6):919-28. doi: 10.1093/intimm/7.6.919.

DOI:10.1093/intimm/7.6.919
PMID:7577800
Abstract

T cell responses against complex antigens are often directed against a limited set of immunodominant determinants. We have studied this phenomenon at the level of cellularly processed peptides recognized by CTL in the B6 anti-BALB.B minor histocompatibility (H) barrier, comprising at least 29 antigen loci. B6 anti-BALB.B CTL always recognized three reverse phase HPLC fractions in BALB.B eluates, whether the latter were obtained from cell lysates or immunoaffinity purified class I molecules. One of these immunodominant epitopes (termed IDE-1) was H-2Db restricted, and two (termed IDE-2 and IDE-3) were H-2Kb restricted. B6 mice were immunized with spleen cells from B6 congenic mice carrying single minor H loci from BALB.B with the aim to assign IDE to given minor H loci and to investigate whether additional epitopes could be identified in the absence of the immunodominant ones. IDE-3 was found to be associated to the locus H-28; in addition five so called cryptic epitopes were defined. Induction of CTL against these epitopes required immunization with cells of the congenic strain; BALB.B spleen cells failed to immunize. One subgroup of these epitopes (those associated to H-8, H-19 and H-25) were nevertheless found to be processed and loaded in class I molecules of BALB.B cells, while there was no evidence for this for H-35 and H-36. For 10 additional congenic strains, no CTL response was detected. The results are discussed in relation to the genetic and molecular basis of minor H antigens, and mechanisms for epitope dominance operating at the level of the APC or responding T cells.

摘要

针对复杂抗原的T细胞反应通常针对一组有限的免疫显性决定簇。我们在B6抗BALB.B次要组织相容性(H)屏障中CTL识别的细胞处理肽水平上研究了这一现象,该屏障包含至少29个抗原位点。B6抗BALB.B CTL总是在BALB.B洗脱物中识别出三个反相高效液相色谱馏分,无论后者是从细胞裂解物中获得还是从免疫亲和纯化的I类分子中获得。其中一个免疫显性表位(称为IDE-1)受H-2Db限制,另外两个(称为IDE-2和IDE-3)受H-2Kb限制。用携带来自BALB.B的单个次要H位点的B6同基因小鼠的脾细胞免疫B6小鼠,目的是将IDE分配到给定的次要H位点,并研究在没有免疫显性表位的情况下是否可以鉴定出其他表位。发现IDE-3与H-28位点相关;此外,还定义了五个所谓的隐蔽表位。针对这些表位诱导CTL需要用同基因品系的细胞进行免疫;BALB.B脾细胞无法进行免疫。然而,发现这些表位的一个亚组(与H-8、H-19和H-25相关的那些)在BALB.B细胞的I类分子中被加工和装载,而对于H-35和H-36则没有证据。对于另外10个同基因品系,未检测到CTL反应。我们结合次要H抗原的遗传和分子基础以及在抗原呈递细胞或反应性T细胞水平上起作用的表位优势机制对结果进行了讨论。

相似文献

1
Dominant and cryptic antigens in the MHC class I restricted T cell response across a complex minor histocompatibility barrier: analysis and mapping by elution of cellular peptides.跨越复杂次要组织相容性屏障的MHC I类限制性T细胞应答中的显性和隐蔽抗原:通过洗脱细胞肽进行分析和定位
Int Immunol. 1995 Jun;7(6):919-28. doi: 10.1093/intimm/7.6.919.
2
Few peptides dominate cytotoxic T lymphocyte responses to single and multiple minor histocompatibility antigens.少数肽主导细胞毒性T淋巴细胞对单一和多种次要组织相容性抗原的反应。
Int Immunol. 1993 Sep;5(9):1003-9. doi: 10.1093/intimm/5.9.1003.
3
Immunodominance in the CTL response against minor histocompatibility antigens: interference between responding T cells, rather than with presentation of epitopes.针对次要组织相容性抗原的细胞毒性T淋巴细胞反应中的免疫显性:反应性T细胞之间的干扰,而非表位呈递的干扰。
J Immunol. 1998 Nov 1;161(9):4499-505.
4
Immunodominant minor histocompatibility antigen peptides presented by H2Db molecules.由H2Db分子呈递的免疫显性次要组织相容性抗原肽。
Transplantation. 1997 Nov 15;64(9):1323-30. doi: 10.1097/00007890-199711150-00015.
5
The molecular and functional characterization of a dominant minor H antigen, H60.一种显性次要组织相容性抗原H60的分子与功能特性
J Immunol. 1998 Oct 1;161(7):3501-9.
6
Immunization with dendritic cells breaks immunodominance in CTL responses against minor histocompatibility and synthetic peptide antigens.用树突状细胞进行免疫接种可打破针对次要组织相容性抗原和合成肽抗原的CTL反应中的免疫优势。
J Leukoc Biol. 1999 Aug;66(2):268-71. doi: 10.1002/jlb.66.2.268.
7
On the mechanisms of immunodominance in cytotoxic T lymphocyte responses to minor histocompatibility antigens.关于细胞毒性T淋巴细胞对次要组织相容性抗原反应中免疫显性的机制
Eur J Immunol. 1997 Feb;27(2):421-30. doi: 10.1002/eji.1830270212.
8
Induction and characterization of minor histocompatibility antigens. Specific primary cytotoxic T lymphocyte responses in vitro.次要组织相容性抗原的诱导与特性。体外特异性原发性细胞毒性T淋巴细胞反应。
J Immunol. 1988 Feb 1;140(3):723-9.
9
The preferential cytolytic T lymphocyte response to immunodominant minor histocompatibility antigen peptides.针对免疫显性次要组织相容性抗原肽的优先细胞溶解性T淋巴细胞反应。
Transplantation. 1996 Jul 27;62(2):283-91. doi: 10.1097/00007890-199607270-00022.
10
Immunodominance in the T cell response to multiple non-H-2 histocompatibility antigens. IV. Partial tissue distribution and mapping of immunodominant antigens.T细胞对多种非H-2组织相容性抗原反应中的免疫显性。IV. 免疫显性抗原的部分组织分布及定位
J Immunol. 1987 Oct 1;139(7):2166-71.

引用本文的文献

1
Neurological syndromes driven by postinfectious processes or unrecognized persistent infections.由感染后过程或未被识别的持续性感染驱动的神经综合征。
Curr Opin Neurol. 2018 Jun;31(3):318-324. doi: 10.1097/WCO.0000000000000553.
2
Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies.血液系统恶性肿瘤中的抗原发现与治疗靶点
Cancer J. 2017 Mar/Apr;23(2):115-124. doi: 10.1097/PPO.0000000000000257.
3
Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation.
用于鉴定血液系统恶性肿瘤中T细胞识别的肿瘤抗原的策略,以改善异基因血液和骨髓移植后的移植物抗肿瘤反应。
Biol Blood Marrow Transplant. 2015 Jun;21(6):1000-7. doi: 10.1016/j.bbmt.2014.11.001. Epub 2014 Nov 20.
4
Therapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasis.用重组腺病毒进行治疗性疫苗接种可减少实验性内脏利什曼病的脾脏寄生虫负担。
J Infect Dis. 2012 Mar 1;205(5):853-63. doi: 10.1093/infdis/jir842. Epub 2012 Feb 1.
5
A single nucleotide polymorphism in the Emp3 gene defines the H4 minor histocompatibility antigen.Emp3基因中的一个单核苷酸多态性决定了H4次要组织相容性抗原。
Immunogenetics. 2003 Aug;55(5):284-95. doi: 10.1007/s00251-003-0581-x. Epub 2003 Jul 4.
6
Differences in MHC-class I presented minor histocompatibility antigens extracted from normal and graft-versus-host disease (GVHD) mice.从正常小鼠和移植物抗宿主病(GVHD)小鼠中提取的主要组织相容性复合体I类呈递的次要组织相容性抗原的差异。
Clin Exp Immunol. 2003 Apr;132(1):46-52. doi: 10.1046/j.1365-2249.2003.02115.x.
7
Generation of CD8+ T cells specific for transporter associated with antigen processing deficient cells.针对与抗原加工缺陷细胞相关的转运体的CD8 + T细胞的产生。
Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11496-501. doi: 10.1073/pnas.94.21.11496.
8
Antigen processing by proteasomes: insights into the molecular basis of crypticity.蛋白酶体对抗原的加工处理:对隐蔽性分子基础的见解。
Mol Biol Rep. 1997 Mar;24(1-2):63-7. doi: 10.1023/a:1006808824631.
9
H4 and CTT-2 minor histocompatibility antigens: concordant genetic linkage and migration in two-dimensional peptide separation.H4和CTT-2次要组织相容性抗原:二维肽分离中的一致遗传连锁与迁移
Immunogenetics. 1996;44(5):400-4. doi: 10.1007/BF02602787.